Tag Archives: Biologics

The drug class of 2011 was larger than the past few graduating classes. We count over 30 new “innovative” drugs found among the list of FDA approvals last year. This is in contrast to the 20-something range of the past few years. On the list are some clear breakthrough treatments and a few glimpses of “the future of biotech”. The specific drugs are listed further below, but first a big picture view: Ten of the approvals were for biologics, Read More >

By David Welch, President/Senior Producer at M2 MultiMedia It had been five years since I produced Biotechnology: Knowledge Serving Life, a video that featured breast cancer patient Lori Lober and her then five year anniversary of being cancer free. Diagnosed with Stage IV metastatic breast cancer in 2000 Lori had been admitted to an advanced clinical trial for a promising new biologic. Today, Lori credits her treatment for helping to save her life. During the Read More >

This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4. Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a. Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >

Huffington Post: Data Exclusivity: Getting the Balance Right A great article on the downsides of cutting or removing data exclusivity provisions for biologics. The article points out that data protection is needed to enhance safety and create incentives to research and produce new innovative drugs that cost billions of dollars. However, the author argues that the period must be limited somehow (not 50 years) to ensure generics can entire the market and lower costs. Finally, the author states that lowering the data exclusivity Read More >

2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >